The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrating early palliative care in advanced sarcoma patients for enhanced quality of life: The SARQUALITY study.
 
Catherine Weadick
Travel, Accommodations, Expenses - Janssen; MSD
 
Natalie Pulenzas
No Relationships to Disclose
 
Harleen Toor
No Relationships to Disclose
 
Victor Cellarius
No Relationships to Disclose
 
Haydée Williams Sanchez
No Relationships to Disclose
 
Jasjeet Matharu
No Relationships to Disclose
 
Abdulazeez Salawu
Honoraria - Bayer; Medison
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Knight Therapeutics; Medison; Taiho Pharmaceutical
Research Funding - Amgen; EMD Serono; PTC Therapeutics; SERVIER; Torl Biotherapeutics
 
Geoffrey Watson
Honoraria - Gilead Sciences; Knight Therapeutics; Pfizer
Consulting or Advisory Role - Novartis
Research Funding - Pfizer
Travel, Accommodations, Expenses - Abbvie
 
Abha Gupta
No Relationships to Disclose
 
Erica Koch Hein
Speakers' Bureau - MSD Oncology; Pfizer
 
Albiruni Abdul Razak
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Clinical Research Malaysia; Inhibrx; Medison; UpToDate
Research Funding - 23 and Me; Abbisko Therapeutics (Inst); Abbvie; Adaptimmune; Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Biosciences (Inst); Daiichi Sankyo; Deciphera; Frontier Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline; Intensity Therapeutics (Inst); Iterion Therapeutics; Karyopharm Therapeutics; Kelun (Inst); Merck; Neoleukin Therapeutics; Pfizer; Polaris (Inst); Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison